Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/Sales ratio is N/A as of 2026-10-06T19:18:41.728Z.
Calculation as of: 2026-10-06T19:18:41.728Z.
Quote observation: 2026-10-06T19:15:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e1553418876f95fd726688d6af936ce5a4046000e23636182a7ec29874c901e9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/SALES RATIO
N/A
Telomir Pharmaceuticals, Inc. Common Stock
Market Cap
$81.95M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$81.90M
EV/Sales Ratio
32.14x
TTM Avg
52.52x
3Y Avg
427.47x
5Y Avg
706.12x
Market Cap
$81.88M
EV/Sales Ratio
N/A
TTM Avg
9472.81x
3Y Avg
14921.28x
5Y Avg
40247.63x
Market Cap
$82.85M
EV/Sales Ratio
145.89x
TTM Avg
202.08x
3Y Avg
199.51x
5Y Avg
216.66x
Market Cap
$80.25M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$83.18M
EV/Sales Ratio
62.89x
TTM Avg
119.91x
3Y Avg
82.00x
5Y Avg
251.31x
Market Cap
$84.14M
EV/Sales Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/SALES RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Telomir Pharmaceuticals, Inc. Common Stock (TELO) | $81.95M | N/A | N/A | N/A | N/A |
| Humacyte, Inc. (HUMA)vs › | $81.90M | 32.14x | 52.52x | 427.47x | 706.12x |
| ProMIS Neurosciences, Inc. (PMN)vs › | $81.88M | N/A | 9472.81x | 14921.28x | 40247.63x |
| LENSAR Inc (LNSR)vs › | $82.53M | 1.18x | 1.93x | 1.60x | 1.28x |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.85M | 145.89x | 202.08x | 199.51x | 216.66x |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $80.25M | N/A | N/A | N/A | N/A |
| MediciNova, Inc. (MNOV)vs › | $83.18M | 62.89x | 119.91x | 82.00x | 251.31x |
| Nutriband Inc. (NTRB)vs › | $80.11M | 47.53x | 23.70x | 23.39x | 21.39x |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.14M | N/A | N/A | N/A | N/A |
| vTv Therapeutics Inc. (VTVT)vs › | $79.15M | N/A | 5027.01x | 2607.85x | 1729.21x |
Enterprise Value (EV) = Market Cap + Total Debt - Cash
Sales = Total Revenue (TTM)
EV/Sales is commonly used because:
Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.
EV/Sales = Enterprise Value / Revenue (TTM)
Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
